Dose escalation is ongoing in the TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), phase 1/2 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2 mutant and other HRD+ (homologous recombination deficient) cancers. The first patient dosed was announced in January 2024.Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Search 
+86 21 5895 0110 
